Sun Pharmaceutical Industries Ltd Soars 6.94% | Espresso Shot of the Day

EspressoLogy

Espresso Shot of the Day - Sun Pharmaceutical Industries Ltd up by 6.94 percent

February 01, 2022
Espresso Shot of the Day - Sun Pharmaceutical Industries Ltd up by 6.94 percent

SUN PHARMACEUTICAL INDUSTRIES LTD 892.05  (+6.94%) BSE – INE044A01036 | Feb 1, 2022.


From humble beginnings in 1983, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. They are the largest pharmaceutical company in India. In the US, they are among the top 10 generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market. Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, the company provides high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Recent Drivers

  • On Jan 31, 2022, Sun Pharma reported Net Sales of Rs.9,863.06 crores in December 2021, up 11.61% from Rs.8,836.78 crores in December 2020.
  • On Jan 31, 2022, the company reported a Quarterly Net Profit of Rs.2,058.80 crores in December 2021, up 7.6% from Rs.1,913.41 crores in December 2020.
  • On Jan 27, 2022, SUN PHARMACEUTICAL LTD reported that its’ subsidiary has launched Cequa, a new treatment for dry eye disease, in Canada.
  • On Dec 28, 2021, the company reported that its’ subsidiary has received emergency use authorization (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD and Ridgeback's antiviral drug molnupiravir.
  • On Dec 28, 2021, SUN PHARMACEUTICAL LTD reported that it is planning to set up a new manufacturing facility in Andhra Pradesh.
  • On Dec 16, 2021, the company reported that one of its wholly owned subsidiaries has received the final approval from US FDA for its abbreviated new drug application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial single-dose vial.
 (Sources: Business standard, Moneycontrol)


Technical Force*

  • S&P BSE SENSEX month till date gain up by 1.46%
  • Traded on 52 Week high value 895.40
  • Spurt in volume by more than 1.72 times, 3 months avg. volume: 167,646
  • Quantity traded: 3,971,125 | Deliverable Quantity: 1,03,769 (26.13%)
  • Stock price has jumped more than 55% from a one-year-low level: 561.65 (Feb 24, 2021)
  • Daily RSI (14) is near Overbought territory today
  • 52-week-high: 895.40 | 52-week-low: 561.65


Key Pivot  (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

1247.50

1049.20

947.30

749.00

647.10

448.80

346.90

70.00

Fibonacci Pivot

1049.20

934.52

863.68

818.05

749.00

679.95

634.32

563.48

448.80


Today’s Close

892.05

SMA

BSE

10 DAY

828.52

20 DAY

834.54

50 DAY

800.98

200 DAY

752.19


Some Key Ratios (Source: BSE)

Market Cap:  2,14,027.42 Crores

PE: 103.34

OPM%: 25.50

ROE%: 7.61

Promoters holding%: 54.48

Prev. Close: 834.15


*Chart and Technical Force data from the Binge desktop app
The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan Comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comrade Private Limited is under no obligation to update the information in this document from time-to-time.


Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.